Qin Y, Ma FY, Zhang Z, Zhao CH, Huang B. Vascular endothelial growth factor pathway’s influence on bevacizumab efficacy in metastatic colorectal cancer treatment. World J Gastrointest Oncol 2024; 16(11): 4514-4517 [PMID: 39554750 DOI: 10.4251/wjgo.v16.i11.4514]
Corresponding Author of This Article
Biao Huang, PhD, Research Fellow, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 928, No. 2 Street, Qiantang District, Hangzhou 310018, Zhejiang Province, China. jswxhb@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yuan Qin, Fu-Yuan Ma, Zhi Zhang, Chen-Hao Zhao, Biao Huang, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China
Author contributions: Huang B and Qin Y designed this study; Qin Y and Ma FY contributed to the writing and editing of the manuscript; Zhang Z and Zhao CH conducted the reference analyses.
Supported byThe Natural Science Foundation of Zhejiang Province, No. LQ23H050005; The Scientific Research Project of Zhejiang Provincial Education Department, No. Y202250731 and No. Y202353130; China Students’ Innovation and Entrepreneurship Training Program, No. 202310338044; and China Postdoctoral Science Foundation, No. 2022M721720.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Biao Huang, PhD, Research Fellow, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 928, No. 2 Street, Qiantang District, Hangzhou 310018, Zhejiang Province, China. jswxhb@163.com
Received: July 24, 2024 Revised: September 17, 2024 Accepted: September 25, 2024 Published online: November 15, 2024 Processing time: 92 Days and 21.7 Hours
Abstract
In this article, an article published in the World Journal of Gastrointestinal Oncology, which focuses on whether the expression of programmed death-ligand 1 (PD-L1) affects the effectiveness of chemotherapy regimens, including bevacizumab, in treating patients with colorectal cancer (CRC). Through neutralization of vascular endothelial growth factor (VEGF), bevacizumab inhibits tumor angiogenesis, impairing neovascularization and thereby depriving the tumor of essential nutrients and oxygen. Conversely, PD-L1 binding to VEGF receptor 2 promotes angiogenesis, supporting tumor vasculature. The interplay between these pathways complicates the assessment of bevacizumab’s efficacy in cancer therapy, notably in CRC, where VEGF and PD-L1 significantly affect treatment response. This review examines metastatic CRC treatment strategies, focusing on bevacizumab’s mechanism of action and the role of PD-L1 in this therapeutic context.
Core Tip: In the management of colorectal carcinoma, bevacizumab wields its therapeutic impact via the neutralization of vascular endothelial growth factor (VEGF), a paramount mediator of intratumoral angiogenesis. This inhibitory action on VEGF obstructs neovascularization, consequently sequestering the essential sustenance of nutrients and oxygen requisite for tumoral proliferation and viability. Contrarily, the interaction between programmed death-ligand 1 and VEGF receptor 2 catalyzes the genesis of novel vasculature that sustains and nurtures the neoplasm, thereby potentiating angiogenic processes.
